Peter Blume-Jensen - 21 Aug 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
21 Aug 2023
Net transactions value
$0
Form type
4
Filing time
23 Aug 2023, 16:19:55 UTC
Previous filing
01 Jun 2023
Next filing
16 Nov 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Award $0 +493,994 +21% $0.000000 2,897,696 21 Aug 2023 Direct F1
holding ACRV Common Stock 320,705 21 Aug 2023 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 1/3rd shall vest on the one-year anniversary of the grant date, and the remaining RSUs shall vest in eight equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F2 These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.